Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone

US8039473B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Andre Bubendorf · Uffheim, FR
• Annette Deynet-Vucenovic · Soest, DE
• Ralph Diodone · Breisach am Rhein, DE
• Olaf Grassmann · Soest, DE
• Kai Lindenstruth · Soest, DE
• Emmanuel Pinard · Rixheim, FR
• Franziska E. Rohrer · Riehen, CH
• Urs Schwitter · Reinach, CH

Key dates

• Filing date: Jul 22, 2010
• Grant date: Oct 18, 2011
• Expiry date: Jul 22, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.